Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Adaptimmune
Biotech
Adaptimmune questions own longevity, axes preclinical funding
Adaptimmune is cutting enrollment for clinical programs and evaluating strategic options in efforts to save cash.
Gabrielle Masson
Mar 20, 2025 2:04pm
Adaptimmune's cell therapy hits key goal in pivotal sarcoma test
Nov 13, 2024 2:57pm
Galapagos selects Adaptimmune cell therapy in $665M collab
May 31, 2024 9:40am
Genentech axes $3B Adaptimmune cell therapy deal
Apr 12, 2024 11:22am
Trio of biotechs toss programs to discard pile
Nov 9, 2023 11:23am
FDA's Peter Marks doesn't plan to retire soon—Chutes & Ladders
Aug 4, 2023 9:30am
